The role of microRNA genes in papillary thyroid carcinoma

• Huiling He

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Krystian Jazdzewski

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Wei Li

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Sandya Liyanarachchi

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Rebecca Nagy

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Stefano Volinia

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• George A. Calin

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Chang-gong Liu

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Kaarle Franssila

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Saul Suster

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Richard T. Kloos

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Carlo M. Croce

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

• Albert de la Chapelle

  Human Cancer Genetics Program, Department of Pathology, and Departments of Internal Medicine and Radiology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; and Department of Pathology, Helsinki University Central Hospital, FIN-00029, Helsinki, Finland

抄録

Apart from alterations in the RET/PTC-RAS-BRAF pathway, comparatively little is known about the genetics of papillary thyroid carcinoma (PTC). We show that numerous microRNAs (miRNAs) are transcriptionally up-regulated in PTC tumors compared with unaffected thyroid tissue. A set of five miRNAs, including the three most up-regulated ones (miR-221, -222, and -146), distinguished unequivocally between PTC and normal thyroid. Additionally, miR-221 was up-regulated in unaffected thyroid tissue in several PTC patients, presumably an early event in carcinogenesis. Tumors in which the up-regulation (11- to 19-fold) of miR-221, -222, and -146 was strongest showed dramatic loss of KIT transcript and Kit protein. In 5 of 10 such cases, this down expression was associated with germline single-nucleotide changes in the two recognition sequences in KIT for these miRNAs. We conclude that up-regulation of several miRs and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation.

収録刊行物

• Proceedings of the National Academy of Sciences

  Proceedings of the National Academy of Sciences 102 (52), 19075-19080, 2005-12-19

  Proceedings of the National Academy of Sciences

キーワード

• Multidisciplinary

詳細情報

• CRID: 1361981470507400448
• NII論文ID: 80017685237
• DOI: 10.1073/pnas.0509603102
• ISSN: 10916490
• ISSN: 00278424
• Web Site: https://pnas.org/doi/pdf/10.1073/pnas.0509603102
• データソース種別:
  • Crossref
  • CiNii Articles